Abstract
Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / therapeutic use*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Biopsy
-
Bone Marrow / pathology
-
Drug Administration Schedule
-
Female
-
Humans
-
Hydroxyurea / therapeutic use
-
Infusions, Intravenous
-
Injections, Subcutaneous
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Male
-
Middle Aged
-
Pilot Projects
-
Plicamycin / administration & dosage
-
Plicamycin / therapeutic use*
-
Survival Rate
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents
-
Interferon-alpha
-
Plicamycin
-
Hydroxyurea